|
||||||||||||||||
| HUM-MOLGEN -> Events -> Meetings and Conferences | ||||||||||||||||
| Genomics and Proteomics | ||||||||||||||||
| August 27, 2002 | ||||||||||||||||
|
marcus evans, Geneva, Switzerland 21-22 January 2003 |
||||||||||||||||
| Organized by: | marcus evans | |||||||||||||||
| Invited Speakers: | Prof. Dr. Thomas R. Weihrauch, Senior Vice President Global Medical Strategy and Relations, BAYER AG PHARMACEUTICAL RESEARCH CENTRE. Bernard Amegadzie, Group Leader – Gene Expression Technology, ELI LILLY & COMPANY. Dr. Jaap Venema, Head of Department Target Biology, SOLVAY PHARMACEUTICALS B.V.. Dr. Jan van Oostrum, Head of Proteome Sciences, NOVARTIS PHARMA AG . Dr. Stefan Evers, Senior Scientist, F. HOFFMANN LA ROCHE. Brad Guild, Director of Biomarker Discovery, MILLENNIUM PHARMACEUTICALS INC . Dr. Reuven Agami, Group Leader, Tumour Biology Division , THE NETHERLANDS CANCER INSTITUTE. Ulla Sidelmann, Manager, Applied Trinomics, NOVO NORDISK. Christian Meisel M.D., Group Leader, Pharmacogenetics and Clinical Pharmacology, HUMBOLDT UNIVERSITÄT ZU BERLIN / CHARITÉ. and etc.... |
|||||||||||||||
| Deadline for Abstracts: | ||||||||||||||||
| Registration: | +44 20 7647 2325 | |||||||||||||||
| E-mail: | olas@marcusevansuk.com | |||||||||||||||
| Posted by: | Ola Samuelsson | |||||||||||||||
| Host: | 194.74.216.2 | |||||||||||||||
|
||||||||||||||||
|
Generated by meetings and positions 5.0 by Kai Garlipp |
||||||||||||||||